司美格鲁肽改善精神分裂症合并糖尿病前期患者的胰岛素敏感性与β细胞功能:HISTORI试验
HISTORI试验为30周双盲随机对照研究,154例接受第二代抗精神病药的精神分裂症合并糖尿病前期及超重/肥胖患者随机接受司美格鲁肽1.0 mg每周一次或安慰剂。结果显示司美格鲁肽显著降低空腹血糖、改善胰岛素敏感性并降低胰岛素抵抗,平均减重9.2 kg且体重下降部分介导了代谢改善,β细胞功能无显著变化。
要点
- 司美格鲁肽1.0 mg每周一次可显著改善胰岛素敏感性并降低胰岛素抵抗。
- 平均体重下降9.2 kg,且体重下降部分介导了胰岛素敏感性和抵抗的改善。
- β细胞功能呈非显著改善趋势,空腹胰岛素和C肽下降亦未达统计学显著。
核心结论
- 司美格鲁肽显著改善胰岛素敏感性、降低胰岛素抵抗、降低空腹血糖并促进显著体重下降。
- 体重下降部分介导了代谢改善,而β细胞功能基本未变。
- 结果支持司美格鲁肽作为减轻该高危人群代谢功能障碍的潜在策略。
研究设计与样本
- 30周、双盲、安慰剂对照随机试验(HISTORI试验)。
- 154例超重或肥胖的精神分裂症合并糖尿病前期且接受第二代抗精神病药的患者随机分配至司美格鲁肽1.0 mg每周一次组(n=77)或安慰剂组(n=77)。
- 141例(91.5%)完成研究;131例提供完整胰岛素数据。
- 参与者56%为女性,平均年龄38.3岁。
- 评估包括空腹血糖、胰岛素、C肽、HOMA2 β细胞功能、HOMA2胰岛素敏感性、HOMA胰岛素抵抗及体重。
主要发现
- 与安慰剂相比,司美格鲁肽显著降低空腹血糖(-0.87 mmol/L [95% CI -1.15, -0.59];P < 0.001)。
- 与安慰剂相比,司美格鲁肽显著改善胰岛素敏感性(8.60 [5.82, 13.65];P = 0.001)。
- 与安慰剂相比,司美格鲁肽显著降低胰岛素抵抗(-0.69 [-1.00, -0.20];P = 0.006)。
- 平均体重下降9.2 kg,并介导了胰岛素敏感性(估计值7.82;P = 0.01)和胰岛素抵抗(估计值-0.75;P = 0.01)的改善。
- 空腹胰岛素(-52.3 pmol/L;P = 0.11)、C肽(-182.9 pmol/L;P = 0.096)及β细胞功能(8.10;P = 0.19)的变化均未达统计学显著。
临床怎么用
- 对于接受第二代抗精神病药、合并糖尿病前期及超重/肥胖的精神分裂症患者,可考虑使用司美格鲁肽1.0 mg每周一次以改善胰岛素敏感性和降低空腹血糖。
- 司美格鲁肽在该人群中可促进显著体重下降,体重下降部分介导代谢改善。
- β细胞功能在本研究中未见显著改善,临床决策时应结合个体情况综合评估。
局限性
- 研究为期30周,长期疗效与安全性未明确。
- β细胞功能、空腹胰岛素及C肽的变化未达统计学显著。
- 体重下降仅部分介导代谢改善,其他机制未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the effects of semaglutide on insulin sensitivity, insulin resistance, and β-cell function and explore whether these changes were mediated by weight loss in overweight or obese individuals with schizophrenia and prediabetes receiving second-generation antipsychotics. RESEARCH DESIGN AND METHODS: In this 30-week, double-blind trial, 154 participants were randomized to semaglutide (n = 77) or placebo (n = 77); 141 (91.5%) completed the study. Baseline and end-of-study assessments included fasting glucose, insulin, C-peptide, HOMA2 of β-cell function, HOMA2 of insulin sensitivity, HOMA of insulin resistance, and body weight. RESULTS: Participants (56% women, mean age 38.3 years) provided complete insulin data in 131 cases. Compared with placebo, semaglutide significantly reduced fasting glucose (-0.87 mmol/L [95% CI -1.15, -0.59]; P < 0.001), improved insulin sensitivity (8.60 [5.82, 13.65]; P = 0.001), and lowered insulin resistance (-0.69 [-1.00, -0.20]; P = 0.006). Mean weight loss was 9.2 kg and mediated improvements in insulin sensitivity (estimate 7.82; P = 0.01) and insulin resistance (estimate -0.75; P = 0.01). Nonsignificant trends were observed toward reduced fasting insulin (-52.3 pmol/L; P = 0.11) and C-peptide (-182.9 pmol/L; P = 0.096), with a modest, nonsignificant increase in β-cell function (8.10; P = 0.19). CONCLUSIONS: Semaglutide significantly improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and promoted substantial weight loss in patients with antipsychotic-induced metabolic disturbances. Weight loss partly mediated the metabolic improvements, while β-cell function remained largely unchanged. These findings support semaglutide as a potential strategy for mitigating metabolic dysfunction in this high-risk population.
引用
- Ganeshalingam AA, Uhrenholt N, Arnfred S, et al. Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. Diabetes Care. 2026. PMID: 41778920. doi:10.2337/dc25-2041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。